U.S. markets closed
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow 30

    31,496.30
    +572.16 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.68 (+1.55%)
     
  • Russell 2000

    2,192.21
    +45.29 (+2.11%)
     
  • Crude Oil

    66.28
    +2.45 (+3.84%)
     
  • Gold

    1,698.20
    -2.50 (-0.15%)
     
  • Silver

    25.30
    -0.17 (-0.65%)
     
  • EUR/USD

    1.1925
    -0.0054 (-0.45%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • GBP/USD

    1.3827
    -0.0067 (-0.48%)
     
  • USD/JPY

    108.2450
    +0.2690 (+0.25%)
     
  • BTC-USD

    48,772.88
    +1,684.85 (+3.58%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

Here's Why You Should Retain Fresenius Medical (FMS) Stock

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Fresenius Medical Care AG & Co. KGaA FMS is well poised for growth on the back of a broad range of dialysis products and services, and its growth strategy for 2020. However, stiff competition remains a concern.

The stock has gained 11.3%, compared with the industry’s growth of 16% in a year’s time. Further, the S&P 500 Index rallied 15% in the same time frame.

The company — with a market capitalization of $23.95 billion — is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. It anticipates earnings to improve 7.8% over the next five years.

Let’s take a closer look at the factors that substantiate the company’s Zacks Rank #3 (Hold).

Primary Headwind

Fresenius Medical has numerous competitors in the field of health care services and sale of dialysis products. Intense competition in the niche markets is likely to hamper the company’s sales opportunities, which in turn can lead to loss of market share.

However, per management, concerns arising from competition pose low risk to the company in the short and mid-term. The company faces aggressive rivalry from HCA Holdings, DaVita HealthCare and Baxter International.

Key Catalysts

Fresenius Medical provides access to a wide range of Dialysis products in its own dialysis clinics and third-party clinics. These include modular machine components, dialyzers, bloodline systems, HD (hemodialysis) solutions, concentrates and water treatment systems.



At year-end 2019, home dialysis accounted for 13% of all treatments in the United States. By 2022, the company aims to perform more than 15% of all dialysis treatment in the United States in a home setting and is on track to achieve this target.

In the United States, the company is collaborating with other dialysis providers to create isolation clinics and dedicated shifts for COVID-19 positive patients. The primary aim of this collaboration is to keep dialysis patients out of the hospital whenever it is possible.

During third-quarter 2020, Fresenius Medical was able to sustain operations in more than 4,000 of its dialysis clinics worldwide without substantial interruption, while minimizing the impact of the pandemic on its staff and patients. Use of telehealth solutions was the primary reason behind this uninterrupted operational performance.

Notably, the company has set up a strong long-term objective called the ‘Growth Strategy 2020’ to plan new initiatives for gaining solid market traction.

Per the postulates of the ‘Growth Strategy 2020’, Fresenius Medical aims to boost revenues to $28 billion by 2020, corresponding to an average annual growth rate of around 10%. In this regard, revenues increased 7% on a year-over-year basis and reached $17.9 billion in recent past, driven by strong performance in Health Care Services. Furthermore, management forecast an increase in revenues in tune with organic growth and acquisitions. At the same time, the company anticipates high single-digit annual growth in net income by 2020.

Which Way are Estimates Headed?

For 2020, the Zacks Consensus Estimate for revenues is pegged at $21.36 billion, indicating an improvement of 9.2% from the prior-year quarter. The same for adjusted earnings per share stands at $2.88, suggesting growth of 13.8% from the year-ago reported figure.

Stocks to Consider

Some better-ranked stocks from the broader medical space are Merit Medical Systems, Inc. MMSI, Align Technology, Inc. ALGN and Thermo Fisher Scientific Inc. TMO, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Merit Medical has a projected long-term earnings growth rate of 12.6%.

Align Technology has an estimated long-term earnings growth rate of 18.3%.

Thermo Fisher has a projected long-term earnings growth rate of 18%.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report
 
Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report
 
Align Technology, Inc. (ALGN) : Free Stock Analysis Report
 
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research